Pioneering Botanical Therapies for Inflammatory and Neurological Diseases

Investor Summary | 2025

Transforming the $1.6 Trillion Pharma Industry with Polyphenol-Based Drug Innovation

Canurta Therapeutics is pioneering a new era in botanical medicine. We develop novel drugs from rare cannabis-derived polyphenols—such as Cannflavin A & B—to address inflammatory and neurological conditions, beginning with ALS.

Led by a seasoned team in cannabinoid science and clinical development, our pipeline includes trial-ready and preclinical assets backed by global IP, regulatory momentum, and a transformative approach to drug discovery.

Why Invest

Innovative Pipeline

CNR-401 leads a growing pipeline targeting ALS, Alzheimer’s, and inflammation—built on multi-pathway compounds and validated preclinical data.

Breakthrough Compounds

Cannflavins A & B—30x stronger than aspirin—are exclusive to Canurta.

Regulatory & Market Traction

Orphan Drug paths in the U.S. and EU, with global entry points in Australia, Canada, Brazil and Germany.

AI-Driven Drug Development

PolyKye™ accelerates adaptive, multi-target drug development and enables precision across a scalable pipeline.

Proven Leadership

Veterans from GW Pharma—the only company to have an FDA-approved cannabis-based drug.

Early Revenue

ALS programs launch in 2025 with multi-year agreements totaling up to $67M across Brazil and Germany.

Pioneers in Botanical Therapeutics

Canurta Day Video Series Email Image.jpg

Founded in 2021, Canurta develops polyphenol-based drugs for neurological and inflammatory conditions. Our lead candidate, CNR-401, enters ALS trials in 2025 with early commercial programs in Brazil and Germany. Backed by over $13M in capital and $3.22M in non-dilutive funding, global IP, and GMP infrastructure, we are bridging nature with next-generation medicine.

The Problem and Our Solution

The Problem

Chronic inflammation and neurodegeneration underpin many of the world’s most devastating conditions. Current treatments are slow to develop, limited in efficacy, and often mono-targeted.

The Solution

Canurta’s therapies use rare cannabis polyphenols to target multiple pathways simultaneously. With a strong safety profile, our standardized, clinically-guided formulations go beyond traditional cannabinoids.

CNR-401: A Botanical Breakthrough for ALS

CNR-401 is a proprietary liquid botanical drug composed of 10 active compounds, including cannflavin A, designed to relieve symptoms and slow disease progression in ALS and other neurodegenerative diseases. First-in-human trials will begin in 2025.

CNR-401: Neurodegenerative Care | Canurta Therapeutics

CBD

Other Minor Cannabinoids

Terpenoids

CFA

Preclinical Highlights

Restored 85% motor function in zebrafish ALS model

Broader gene modulation than Edaravone, including NOS2 and DOCK2

Reduced anxiety-like behavior by 80%, with effects comparable to CBD

Confirmed non-toxicity at therapeutic doses

Mechanism of Action (MoA)

CNR-401 targets multiple systems impacted by ALS:

Neuron Survival – Anti-inflammatory, reduces glutamate toxicity

Motor Function – Enhances spasticity, coordination, and strength

Respiratory Health – Improves lung function and secretion clearance

Cognitive & Emotional – Reduces anxiety and supports mood

Cellular Defense – Boosts mitochondrial and antioxidant function

CNR-401 vs. Standard ALS Therapies

Feature	CNR-401	Edaravone	Riluzole
Annual Cost	~30K CAD (NA)	~$185K	~$5.4K
IP & Exclusivity	Global patents + 7-10 yrs exclusivity	Expired	Expired
Regulatory Path	Botanical + Orphan	Small molecule	Small molecule
Mechanism	Multi-target	Single Target: Free radical scavenger	Single Target: Glutamate inhibition
Symptom Relief	Broad	None	Limited
Disease Modification	Strong Potential	Modest	Modest
Safety Profile	Oral, favorable	IV, known side effects	Requires live monitoring

The Backbone: Cannflavins

Cannflavins A & B are rare, non-psychoactive cannabis-derived polyphenols with 30x the anti-inflammatory potency of aspirin. They inhibit key enzymes like mPGES-1 and 5-LO, showing efficacy comparable to Zileuton, with broader therapeutic potential across neuroprotection and pulmonary health. Canurta holds exclusive global IP across extraction, formulation, and therapeutic use.

The Engine: Polykye™

PolyKye™ is Canurta’s proprietary AI platform that transforms rare plant compounds into next-gen therapies. It predicts compound behavior, adapts based on lab and clinical data, and enables ongoing optimization—cutting R&D timelines and powering a continuously evolving pipeline. Blockchain tracking across development stages ensures data integrity and transparent decision-making.

Business Model

Canurta is built for scalable growth through a diversified approach:

Botanical Rx:

Global drug development for ALS, neurological and inflammatory diseases

Licensing &
Co-Development:

IP and formulation partnerships with pharma

Vertical Integration:

Canurta Naturals, our parallel nutraceutical line

Go-to-Market Strategy

Early access programs in Brazil and Germany generate early revenue and real-world evidence (RWE) to fuel global expansion.

Brazil

ANVISA-approved Compassionate Use entry, distributor secured

Germany

Early ALS access under medical cannabis framework, partner discussions in progress

RWE

Informs trial design and supports regulatory acceleration

Patient Engagement

The Healing Project (THP) drives co-creation, feedback, and advocacy

Market Opportunity

$60B+ neurodegenerative disease market

$969M ALS market by 2028

Only two FDA-approved botanical drugs exist today—an untapped category

CNR-401 serves as a pipeline-in-a-product for ALS, Alzheimer’s, and beyond

7–10 years market exclusivity via Orphan Drug protections

Projected Neurodegenerative Disease Market

Our Traction

Over $13M total funding to date ($3.22M non-dilutive)

$11M Sales Contract & Carmen's Medicinals (Brazil), backed by Export Development Canada

23 patents filed across 7 major markets (US, CA, EU, MX, IN, CN, BR)

GMP manufacturing in U.S. with global reach

HALOS first-in-human trial launches in Australia (IND exempt) in Q3 2025

Commercial pilots launch Q4 2025 (Brazil + Germany)

AI platform PolyKye™ in early MVP stage

Strategic partnerships with top clinical and academic groups

Team

Investment Opportunity

$5M CAD Convertible Note | $2.2M secured to date

Cap: $34M | Close: June 30, 2025

Exit Potential

Liquidity Event Target: Before End of Q2 2026

Alternative Exits: Licensing / Acquisition (e.g., GW Pharma $7.2B)

ROI Potential: Up to 102.8x

What's Next

ALS pilots launch in Brazil & Germany (early access + RWE) (Q3 2025)

Convertible raise and public listing preparation underway (Q4 2025–2026)

FDA pre-IND and Orphan Drug Designation (Q1 2025)

HALOS first-in-human trial (Australia) (Q3/Q4 2025)

Join the Botanical Medicine Revolution

We’re not just building a biotech company. We’re creating a new category of therapeutics—rooted in nature, refined by science, and driven by purpose.

Let’s shape the future of medicine, together.

Book a Call